Institut Curie — Sponsor Intelligence | 19 EU Trials

Filter these 19 trials by condition, phase, country and more.

Open in Search →

19 Registered trials

8 Recruiting

11 Completed trials

1 Countries active

23 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase I

Phase III: 2 Phase II: 12 Phase I/II: 2 Phase I: 2 Phase I (FiH): 1

100%

11 of 11 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Triple negative breast cancer 4 Breast cancer metastatic 2 Retinoblastoma 1 HER2 negative breast cancer 1

Top IMPs

(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE 5 CARBOPLATIN 5 ETOPOSIDE 4 CYCLOPHOSPHAMIDE 3 VINCRISTINE SULFATE 3 ATEZOLIZUMAB 2 DOXORUBICIN HYDROCHLORIDE 2 TRASTUZUMAB 2 TUCATINIB 2 EPIRUBICIN HYDROCHLORIDE 1 FLUOROESTRADIOL F-18 1 FULVESTRANT 1

All trials

19 total

Early detection of triple negative breast cancer relapse (CUPCAKE) Not authorised

2022-501562-22-00 Phase II 1 country (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHY…
Tucatinib and trastuzumab in HER3-mutant and HER2-not amplified metastatic breast cancer Pending

2024-519624-24-00 Phase II 1 country TRASTUZUMAB; TUCATINIB
Early detection of triple negative breast cancer relapse (CUPCAKE) Recruiting

2022-501562-22-01 Phase II 1 country (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHY…
Prospective cohort involving repeated medical PET-CT imaging with a new radiotracer (FAPI) Recruiting

2024-512467-31-00 Phase I/II 1 country (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHY…
68Ga-FAPI-46 PET/CT for predicting histological response in triple-negative breast cancer Recruiting

2023-507860-37-00 Phase I/II 1 country (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHY…
EstroTEP and circulating biomarkers for ER-positive HER2-negative metastatic breast cancer patients Recruiting

2023-506282-66-00 Phase III 1 country FLUOROESTRADIOL F-18
Tucatinib in combination with Oral Etoposide (VP16) and Trastuzumab in Patients with metastatic HER2+ Breast cancer (TUC-TOC) Recruiting

2022-500743-20-00 Phase II 1 country ETOPOSIDE; TRASTUZUMAB; TUCATINIB
OFOBA : Opioid-Free versus Opioid-Based Anaesthesia for free-flap reconstruction surgery of the breast: A phase III multicentric randomized… Recruiting

2024-513308-32-00 Phase III 1 country
RETINO 2018: conservative treatment for retinoblastoma: efficacy of the new management strategies and visual outcome Recruiting

2024-514025-30-00 Phase II 1 country CARBOPLATIN; ETOPOSIDE; MELPHALAN HYDROCHLORIDE; TOPOTECAN; VINCRISTINE SULFATE
Conservative treatment of patients with retinoblastoma Recruiting

2024-517275-21-00 Phase II 1 country CARBOPLATIN; ETOPOSIDE; MELPHALAN; VINCRISTINE SULFATE
Tiragolumab and atezolizumab associated with chemotherapy in triple negative breast cancer Ended

2022-501561-51-00 Phase II 1 country (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHY…
A phase II, monocentric, single arm trial evaluating the efficacy and safety of Pembrolizumab in combination with Lenvatinib in metastatic U… Ended

2024-514657-30-00 Phase II 1 country
Loc-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction tr… Ended

2024-515331-30-00 Phase I (FiH) 1 country
RB SFCE 2009 : Adjuvant treatment in extensive unilateral retinoblastoma primary enucleated Ended

2024-514844-10-00 Phase II 1 country CARBOPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; THIOTEPA; VINCRISTINE SULFATE
M1774 (oral ATR inhibitor) in Combination with PLX038 (Topo1 inhibitor) with dose expansion cohorts in patients with advanced solid tumors Ended

2023-505431-12-00 Phase I 1 country
"TOPOLOGY" : A phase II study to evaluate the efficacy and toxicities of PLX038, in patients with locally advanced or metastatic triple-nega… Ended

2022-501507-27-00 Phase II 1 country PEG-7-ETHYL-10-HYDROXYCAMPTOTHECIN
Atezolizumab plus RP1 oncolytic immunotherapy in the NeoAdjuvant setting of Triple-Negative Breast Cancer Ended

2022-502311-12-00 Phase II 1 country ATEZOLIZUMAB; RP1
Milademetan and fulvestrant in GATA3-mutant, ER-positive, HER2-negative advanced or metastatic breast cancer patients (DEMETER) Ended

2022-502360-21-00 Phase II 1 country FULVESTRANT; MILADEMETAN
CLEVER PEPTIDE : Open-label, non-controlled, multicenter, dose escalation, first-in-human clinical trial to evaluate the safety, pharmacokin… Ended

2024-518362-27-00 Phase I 1 country

Showing 1–19 of 19 trials

← All sponsors A–Z